Subcutaneous Vedolizumab Holds Its Own Against Newer UC Therapies in Network Meta-Analysis

This sponsor-funded Bayesian network meta-analysis positions subcutaneous (SC) vedolizumab maintenance against 29 trials of targeted therapies for moderate to severe ulcerative colitis (UC), with relevance for pharmacists advising on maintenance selection, dosing, and safety.

📅 Journal publication: Jul 25, 2026 · Last updated: Oct 24, 2026

vedolizumabadalimumabustekinumabtofacitinibupadacitinibozanimodetrasimodmirikizumabgolimumabinfliximabulcerative colitisnetwork meta-analysisBayesianbiologicsmaintenance therapysubcutaneous Rheumatology / Immunology

Also in Gastroenterology / Hepatology

Background Information

Vedolizumab SC shines in efficacy and safety for ulcerative colitis.

Clinicians face challenges in deciding among various targeted inflammatory bowel disease therapies for ulcerative colitis. Subcutaneous (SC) vedolizumab was comparable or superior in efficacy to most therapies, except adalimumab, and had a favorable safety profile. This Bayesian network meta-analysis provides evidence supporting vedolizumab SC as an effective and safe option for moderate to severe ulcerative colitis. Vedolizumab SC is a strong option for moderate to severe ulcerative colitis, matching or surpassing other therapies in efficacy and safety.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Jiang J, Wojtowicz A, Uyei J, Jin H, Lindsley K, Sanchirico M

Citation: Jiang J, Wojtowicz A, Uyei J, et al. Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update. BMC gastroenterology. 2026;26(1). doi:10.1186/s12876-026-04804-7

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →